Try our Advanced Search for more refined results

Market Rumors: Valeant Pharmaceuticals, Santander, Ardagh

By Chelsea Naso (December 9, 2014, 5:54 PM EST) -- After shelling out $19 billion on 40 acquisitions since 2008, Valeant Pharmaceuticals International Inc. is abandoning its aggressive growth via acquisition strategy to focus on reducing debt and boosting its stock price, Reuters reported Tuesday. It plans to return to its acquisition strategy eventually but for now plans to use capital to pay down debt or buy back shares, the report said, but also noted Valeant is not calling off deal-making entirely and would still snap at a good opportunity....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!